logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5268.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5268.produseast1
Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: An individual patient data meta-analysis | Journal Article / Review | MSF Science Portal
Journal Article
|Review

Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Kwak N, Kim JY, Han A, Berry C, Beumont M, Conor T, Crook A, Dheda K, Fabiane S, Fadeyi MO, Foraida S, Gils T, Thanh T, Hoang T, Jham MA, Murphy RA, Nguyen BH, Mai T, Nguyen P, Nyang'wa BT, Hahn S, Yim JJ
Download

Similar Content
Loading...
Loading...
Loading...
Abstract

BACKGROUND

The optimal dosing strategy of linezolid for treating multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) remains unclear. We conducted an individual patient data (IPD) meta-analysis to determine the optimal linezolid dosing strategy.


METHODS

We searched PubMed, Embase, and Scopus for randomised controlled trials (RCTs) and prospective cohort studies on short-course, all-oral regimens containing linezolid for treating MDR/RR-TB through 31 August 2023. Patients were grouped according to linezolid dosing patterns. Time to treatment success and adverse events≥grade 3 were analysed using the Fine-Gray sub-distribution hazard model.


RESULTS

Of 12 eligible studies, 8 (4 RCTs, 4 prospective) were included. Overall, 945 patients were grouped as follows: group 1 (600 mg linezolid for 8 weeks), group 2 (600 mg for 16 weeks, then 300 mg for 8 weeks), group 3 (600 mg for 39 weeks), and group 4 (1200 mg for 25 weeks). Proportions of patients achieving treatment success were 59·1%, 90·4%, 91·3%, and 96·0%, respectively. Compared with group 2, groups 1 (adjusted sub-distribution hazard ratio [aSHR], 0·24, 95% confidence interval [CI], 0·08-0·71) and 3 (aSHR, 0·36, 95% CI, 0·16-0·81) had lower success rates. While group 4 showed no significant difference in treatment success versus group 2 (aSHR, 0·57, 95% CI, 0·23-1·43), it had a higher rate of adverse events≥grade 3 (aSHR, 2·29, 95% CI, 1·37-3·83).


CONCLUSION

A dosing strategy of 600 mg linezolid daily for 16 weeks, then 300 mg for 8 weeks, could be optimal for treating MDR/RR-TB when considering effectiveness and safety.

Subject Area

antibiotic resistancetuberculosisantimicrobial resistance

Languages

English
DOI
10.1183/13993003.00315-2025
Published Date
17 Jul 2025
PubMed ID
40675768
Journal
European Respiratory Journal
Dimensions Badge